TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18095262

Group type: EXPERIMENTAL
Intervention: Group-based physical training intervention
Number of subjects: 132
Study: 15970873

Group type: EXPERIMENTAL
Intervention: Nonsurgical, transurethral radiofrequency energy (RF) tissue micro-remodeling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment (control)
Number of subjects: 0
Study: 12834861

Group type: EXPERIMENTAL
Intervention: 1x 125 mg oral brivudin for 7 days
Number of subjects: 608

Group type: COMPARATOR
Intervention: 5x 800 mg acyclovir for 7 days
Number of subjects: 608
Study: 11304051

Group type: EXPERIMENTAL
Intervention: 10 mg elemental zinc (n = 136)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Placebo (n = 138)
Number of subjects: 274
Study: 8681923

Group type: EXPERIMENTAL
Intervention: Individualized breast cancer risk counseling (BCRC)
Number of subjects: 239

Group type: COMPARATOR
Intervention: General health education (GHE)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: BCRC and GHE groups
Number of subjects: 239
Study: 2072191

Group type: EXPERIMENTAL
Intervention: Extra-intraoral landmark technique (EIL technique)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Direct technique
Number of subjects: 0
Study: 6823630

Group type: EXPERIMENTAL
Intervention: Epidural pethidine 0.75 mg/kg
Number of subjects: 41

Group type: COMPARATOR
Intervention: Intramuscular pethidine 1.5 mg/kg
Number of subjects: 41
Study: 31607294

Group type: EXPERIMENTAL
Intervention: Decitabine combined with half-course pre-excitation treatment
Number of subjects: 44

Group type: COMPARATOR
Intervention: Routine complete course pre-excitation treatment (Control)
Number of subjects: 44
Study: 28645203

Group type: EXPERIMENTAL
Intervention: Neurosurgical procedures
Number of subjects: 401
Study: 27965223

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (meditation, mild yoga movement, and music), conducted in a group format 1 hour a week for 8 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (meditation, mild yoga movement, and music).
Number of subjects: 0
Study: 24533082

Group type: EXPERIMENTAL
Intervention: Whey protein (25 g; PRO)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Alcohol (1.5 g·kg body mass⁻¹) co-ingested with protein (ALC-PRO)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Alcohol (1.5 g·kg body mass⁻¹) co-ingested with carbohydrate (ALC-CHO)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Energy-matched quantity of carbohydrate (25 g maltodextrin; ALC-CHO)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 8
Study: 22279217

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 20206849

Group type: EXPERIMENTAL
Intervention: DEX‐MDZ (Dexmedetomidine with midazolam)
Number of subjects: 55

Group type: COMPARATOR
Intervention: MDZ (Midazolam only)
Number of subjects: 55
Study: 17419955

Group type: EXPERIMENTAL
Intervention: Supportive‐expressive group therapy (SEGT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 0
Study: 16387985

Group type: EXPERIMENTAL
Intervention: controlled‐release fluvoxamine
Number of subjects: 117
Study: 11940738

Group type: EXPERIMENTAL
Intervention: Standard treatment plus hypothermia for 48 hrs
Number of subjects: 392

Group type: COMPARATOR
Intervention: Standard brain injury treatment
Number of subjects: 392
Study: 9639217

Group type: EXPERIMENTAL
Intervention: Amnioinfusion of normal saline (37 degrees C) at 600 ml/h for 1 h, then 180 ml/h until full cervical dilatation or uterine baseline activity reached 20 mm Hg.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no amnioinfusion).
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Amnioinfusion group.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 42
Study: 8018108

Group type: EXPERIMENTAL
Intervention: 30 energy percent of fat food regimen
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 40 energy percent of fat food regimen
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Endurance physical activity
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Baseline dietary fiber intake
Number of subjects: 20
Study: 2738182

Group type: EXPERIMENTAL
Intervention: Monoamine oxidase inhibitors (MAOIs)
Number of subjects: 18
Study: 1059709

Group type: EXPERIMENTAL
Intervention: Live attenuated vaccine
Number of subjects: 1048

Group type: EXPERIMENTAL
Intervention: Detergent-split subunit vaccine
Number of subjects: 1048

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 1048
Study: 31812490

Group type: EXPERIMENTAL
Intervention: Massage therapy (15 minutes twice per day during phototherapy)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine care during phototherapy
Number of subjects: 50
Study: 30552112

Group type: EXPERIMENTAL
Intervention: Pertuzumab in combination with trastuzumab and chemotherapy
Number of subjects: 381

Group type: COMPARATOR
Intervention: Placebo in combination with trastuzumab and chemotherapy
Number of subjects: 381
Study: 28376288

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 26547464

Group type: EXPERIMENTAL
Intervention: Shared physician-patient incentives
Number of subjects: 1503

Group type: EXPERIMENTAL
Intervention: Physician incentives
Number of subjects: 1503

Group type: EXPERIMENTAL
Intervention: Patient incentives
Number of subjects: 1503

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1503
Study: 23389565

Group type: EXPERIMENTAL
Intervention: Computer navigation (CN) techniques
Number of subjects: 33

Group type: COMPARATOR
Intervention: Fluoroscopic (fluoro) techniques
Number of subjects: 33
Study: 21888861

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 953

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 953
Study: 19793402

Group type: EXPERIMENTAL
Intervention: 0.4 mg scopolamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16814414

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600 mg twice daily)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 14971981

Group type: EXPERIMENTAL
Intervention: rollerboard training
Number of subjects: 58

Group type: COMPARATOR
Intervention: control group (14 cross-country runners)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: other training methods (weight, circuit, ski-specific)
Number of subjects: 58
Study: 11578715

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirofiban with unfractionated heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study: 9406135

Group type: EXPERIMENTAL
Intervention: Prophylactic use of pancreatic enzyme-sodium bicarbonate suspension (5 mL containing lipase 2000 FIP units, amylase 1500 FIP units, protease 100 FIP units, and 90 mg NaHCO3)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Water flushing (control)
Number of subjects: 57
Study: 8482047

Group type: EXPERIMENTAL
Intervention: Endothelin-1 alone (5 pmol/min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Endothelin-1 + Glyceryl trinitrate
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Endothelin-1 + NG-mononmethyl-L-arginine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Endothelin-1 + Prostacyclin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Endothelin-1 + Aspirin (acetylsalicylic acid)
Number of subjects: 6
Study: 3025113

Group type: EXPERIMENTAL
Intervention: Theophylline therapy (sustained release preparation, TheoDur 200 and 300 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Theophylline therapy (sustained release preparation)
Number of subjects: 10
Study: 29127072

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) therapy with a repetition frequency of 2.05Hz and a maximum flux density of 25.3μT (rms)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham PEMF (placebo)
Number of subjects: 70
Study: 26640157

Group type: EXPERIMENTAL
Intervention: Prefabricated foot orthoses
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Rocker‐sole footwear
Number of subjects: 102

Group type: COMPARATOR
Intervention: Usual footwear
Number of subjects: 102
Study: 24709491

Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg orally, tid for 7 days)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control (placebo, 10 mL of sterile water for injection, tid for 7 days)
Number of subjects: 128
Study: 22495138

Group type: EXPERIMENTAL
Intervention: New atrial fibrillation
Number of subjects: 30424

Group type: EXPERIMENTAL
Intervention: History of hypertension
Number of subjects: 30424
Study: 18820825

Group type: EXPERIMENTAL
Intervention: Pioglitazone for 8 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (continued previous treatment)
Number of subjects: 24
Study: 17666353

Group type: EXPERIMENTAL
Intervention: Isoflurane inhalation with FGF rate of 1 L/min, setting concentration 1%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isoflurane inhalation with FGF rate of 1 L/min, setting concentration 2%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isoflurane inhalation with FGF rate of 2 L/min, setting concentration 1%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isoflurane inhalation with FGF rate of 2 L/min, setting concentration 2%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isoflurane inhalation with FGF rate of 3 L/min, setting concentration 1%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isoflurane inhalation with FGF rate of 3 L/min, setting concentration 2%
Number of subjects: 60
Study: 15031839

Group type: COMPARATOR
Intervention: Asymptomatic group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: WAD group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 12759210

Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvest (EVH)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open vein harvest (OVH)
Number of subjects: 60
Study: 7641897

Group type: EXPERIMENTAL
Intervention: Goserelin plus HRT (25 micrograms transdermal 17 beta E2 daily and 5 mg medroxyprogesterone acetate orally daily) for 20 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Goserelin alone, 3.6 mg SC depot every 4 weeks for 24 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Goserelin, 3.6 mg SC depot every 4 weeks for 24 weeks, plus HRT
Number of subjects: 50
Study: 2590331

Group type: EXPERIMENTAL
Intervention: Arthroscopic subacromial decompression
Number of subjects: 20

Group type: COMPARATOR
Intervention: Open acromioplasty
Number of subjects: 20
Study: 790943

Group type: EXPERIMENTAL
Intervention: Synthetic porcine secretin, 333 mug subcutaneously every 4 hr for 10 days
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo injections on the same schedule
Number of subjects: 13
Study: 30062527

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection (1 ml of 2% mepivacaine and 40 mg of triamcinolone)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Blind injection (1 ml of 2% mepivacaine and 40 mg of triamcinolone)
Number of subjects: 56
Study: 27366978

Group type: EXPERIMENTAL
Intervention: Boppy condition (positional support using a Mini Boppy®)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Roll condition (rolled blanket)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Blanket condition (flat blanket)
Number of subjects: 32
Study: 24206541

Group type: EXPERIMENTAL
Intervention: Intensive multifactorial non‐pharmacologic interventions including better compliance with prescribed medication, regular blood pressure measurements, healthy diet, regular physical activity, and cognitive training.
Number of subjects: 202

Group type: COMPARATOR
Intervention: Standard stroke care according to guidelines (control group).
Number of subjects: 202
Study: 23680739

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 716

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 716
Study: 21510308

Group type: EXPERIMENTAL
Intervention: 5000 IE Heparin (0.2 ml of 25000 IE)
Number of subjects: 89

Group type: COMPARATOR
Intervention: 0.2 ml 0.9% NaCL (placebo)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 89
Study: 18608554

Group type: EXPERIMENTAL
Intervention: Tangerine tomato sauce (300 g per day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Red tomato sauce (300 g per day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both tomato sauces
Number of subjects: 21
Study: 16768659

Group type: EXPERIMENTAL
Intervention: FOBT
Number of subjects: 1679

Group type: EXPERIMENTAL
Intervention: FOBT/FS
Number of subjects: 1679

Group type: EXPERIMENTAL
Intervention: CTC
Number of subjects: 1679

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 1679

Group type: EXPERIMENTAL
Intervention: Choice of test with FOBT kit
Number of subjects: 1679

Group type: EXPERIMENTAL
Intervention: Choice of test without FOBT kit
Number of subjects: 1679
Study: 15330955

Group type: EXPERIMENTAL
Intervention: 0.2 mg kg(‐1) intramuscular midazolam by Bioject injector
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.2 mg kg(‐1) subcutaneous midazolam by J‐Tip injector
Number of subjects: 45

Group type: COMPARATOR
Intervention: 0.5 mg kg(‐1) oral midazolam
Number of subjects: 45
Study: 11519531

Group type: EXPERIMENTAL
Intervention: Hyoscine N-butylbromide (10 mg p.o. t.i.d. for 24 h)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11367646

Group type: EXPERIMENTAL
Intervention: Salvia Miltiorrhizae Composita (SMC) 200 mg/kg administered intravenously before operation and during rewarming period
Number of subjects: 18

Group type: COMPARATOR
Intervention: Balanced salt solution (control group)
Number of subjects: 18
Study: 7921099

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including home visits weekly during the first year and biweekly thereafter, and attendance at a child development center 5 days a week from 12 months to 3 years
Number of subjects: 914

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 914
Study: 2454118

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group (CB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention-placebo group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 29618485

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 80

Group type: COMPARATOR
Intervention: Anatomical landmark technique
Number of subjects: 80
Study: 28640529

Group type: EXPERIMENTAL
Intervention: Everolimus (EVR)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Calcineurin inhibitors (CsA)
Number of subjects: 115
Study: 25856035

Group type: EXPERIMENTAL
Intervention: 30‐second injection duration
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 30‐second injection duration and 5‐minute dry cold application
Number of subjects: 60

Group type: COMPARATOR
Intervention: 10-second injection duration with no dry cold application
Number of subjects: 60
Study: 23725491

Group type: EXPERIMENTAL
Intervention: modMA2 (Ti-Zirconium alloy)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: modMA1 (chemically modified hydrophilic acid etched titanium)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: M (hydrophobic machined titanium)
Number of subjects: 30
Study: 22145255

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (2 mL)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Intravenous normal saline (2 mL)
Number of subjects: 178
Study: 19095357

Group type: EXPERIMENTAL
Intervention: 5% hypertonic saline injection (0.25ml) into the infra-patellar fat pad
Number of subjects: 7

Group type: COMPARATOR
Intervention: No pain condition
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Pain condition
Number of subjects: 7
Study: 16866137

Group type: EXPERIMENTAL
Intervention: Coartem
Number of subjects: 56

Group type: COMPARATOR
Intervention: Fansimef
Number of subjects: 56
Study: 12633545

Group type: EXPERIMENTAL
Intervention: Atriobiventricular (A-BiV) pacing for 3 months
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Atriobiventricular (A-BiV) pacing for 12 months
Number of subjects: 34

Group type: COMPARATOR
Intervention: Inactive pacing (ventricular inhibited pacing at 40 beats/min)
Number of subjects: 34
Study: 10702449

Group type: EXPERIMENTAL
Intervention: 0.125% ropivacaine with fentanyl 2 microg/mL
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.125% bupivacaine with fentanyl
Number of subjects: 50
Study: 9061108

Group type: EXPERIMENTAL
Intervention: 1 mg morphine intra-articularly + saline intramuscularly
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 10 mg pethidine intra-articularly + saline intramuscularly
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 10 micrograms fentanyl intra-articularly + saline intramuscularly
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline intramuscularly + 1 mg morphine intra-articularly
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline intramuscularly + 10 mg pethidine intra-articularly
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline intramuscularly + 10 micrograms fentanyl intra-articularly
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline intra-articularly + saline intramuscularly (control group)
Number of subjects: 70
Study: 8173520

Group type: EXPERIMENTAL
Intervention: Boomerang pillows
Number of subjects: 42

Group type: COMPARATOR
Intervention: Straight pillows
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Semi-Fowler's position
Number of subjects: 42
Study: 3594019

Group type: EXPERIMENTAL
Intervention: Hearing aid intervention (fitted for hearing purposes)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Waiting list control group (no intervention for 6 weeks)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Hearing aid use for more than 2 hours daily
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Hearing aid use for less than 2 hours daily
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Pre- and post-fitting scaling
Number of subjects: 39
Study: 31177305

Group type: EXPERIMENTAL
Intervention: Photodynamic diagnosis and 6 weekly optimized mitomycin C instillations
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Malignant cytology
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Current and former smokers
Number of subjects: 131
Study: 29050922

Group type: EXPERIMENTAL
Intervention: Catheter ablation (CA)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Antiarrhythmic medication (AAD)
Number of subjects: 260
Study: 27306420

Group type: EXPERIMENTAL
Intervention: Silicone-based lubricant
Number of subjects: 38

Group type: COMPARATOR
Intervention: Water-based lubricant
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both lubricants
Number of subjects: 38
Study: 26667497

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intranasal sterile saline (Control)
Number of subjects: 0
Study: 23513240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Presence of intraplaque hemorrhage (IPH)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Change in LRNC
Number of subjects: 73
Study: 19875752

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 2754

Group type: EXPERIMENTAL
Intervention: Local treatment strategies
Number of subjects: 2754
Study: 19055622

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: SP plus amodiaquine (AQSP)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Artesunate plus SP (ASSP)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Mutations at dhps‐437 and dhps‐540
Number of subjects: 212
Study: 16540136

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 153

Group type: COMPARATOR
Intervention: Multi-micronutrient supplementation
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 14572568

Group type: EXPERIMENTAL
Intervention: Endoscopic injection of absolute ethanol (group I, n = 42)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Hemoclipping (group II, n = 42)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Combination of both methods (group III, n = 42)
Number of subjects: 126
Study: 11087165

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 0
Study: 8747973

Group type: EXPERIMENTAL
Intervention: Intrathecal octreotide
Number of subjects: 2
Study: 1357894

Group type: EXPERIMENTAL
Intervention: Roxithromycin 150 mg b.i.d. for 10 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: Phenoxymethyl-penicillin 1 g b.i.d. for 10 days
Number of subjects: 19
Study: 2436506

Group type: EXPERIMENTAL
Intervention: aprotinin
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control
Number of subjects: 147
Study: 31474530

Group type: EXPERIMENTAL
Intervention: Darco Plantar Lapidus Plating System® (Wright Medical, Memphis, TN)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Plantar Lapidus Plate® (Arthrex, Naples, FL)
Number of subjects: 12
Study: 29643231

Group type: EXPERIMENTAL
Intervention: OCDC (oxidized autologous whole‐tumor cell lysate) administered alone (cohort 1, n = 5)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: OCDC in combination with bevacizumab (cohort 2, n = 10)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: OCDC in combination with bevacizumab plus low‐dose intravenous cyclophosphamide (cohort 3, n = 10)
Number of subjects: 25
Study: 27858069

Group type: EXPERIMENTAL
Intervention: Anti-gingivitis IgY toothpaste used twice daily for 3 minutes
Number of subjects: 100

Group type: COMPARATOR
Intervention: None anti-gingivitis IgY toothpaste
Number of subjects: 100
Study: 24941838

Group type: EXPERIMENTAL
Intervention: Ligustrazine Hydrochloride (LH) 3 mg/kg intravenously infused and added in CPB priming
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 40